Table 1.

Patient Demographics (N = 30)

Characteristic	Xylitol Group (n = 14)	SOC Group (n = 16)
Sex, n (%)
Female	8(57)	6(36)
Male	6(43)	10(64)
Age, yr, median (range)	14.0 (2–26)	11.5(3–29)
Diagnosis, n (%)
Malignancy	8(57)	8(50)
Immune deficiency	1(7)	3(18)
Bone marrow failure	5(36)	3(18)
Nonmalignant hematology	0	1(6)
Genetic/metabolic	0	1(6)
Conditioning regimen, n (%)
Myeloablative	10(71)	12(75)
Reduced intensity	4(29)	4(25)
Donor type,n(%)
Autologous	8(57)	2(12)
Allogeneic	6(43)	14(88)
Stem cell source, n(%)
Bone marrow	2(14)	6(38)
Peripheral blood stem cells	12(86)	9(56)
Cord blood	0	1(6)